International audienceThis paper addresses the question of national differences as regard the number of triadic patents applied for by inventors from several OECD countries. The key idea is to determine whether such differences should be attributed to differences in R&D expenditures or rather to some other reasons, mainly institutional or behavioural ones. With this aim in view, both a macro-economic analysis, based on aggregate data for triadic patent counts and R&D expenditures and a micro-economic analysis based on firms' data from three selected sectors are performed. In both cases, the methodological focus is made on the introduction, the definition and the estimation of a national index of relative efficiency in standard count data mo...
Has the USA overtaken Europe as the powerhouse of new medicines? If so, is this attributable to a fl...
International patenting activity is a source of international technology diffusion.� However, techno...
Has the USA overtaken Europe as the powerhouse of new medicines? If so, is this attributable to a fl...
International audienceThis paper addresses the question of national differences as regard the number...
We investigate cross country differences in patent propensity in the European Union using the Europe...
In this article, we empirically investigate the effect of Research and Development (R&D) flows o...
This chapter uses patent applications as an innovation indicator and compares the trends and Structu...
This paper examines whether there are differences in private R&D investment performance between the ...
This paper examines whether there are differences in private R&D investment performance between the ...
This paper examines whether there are differences in private R&D investment performance between the ...
This paper offers an empirical examination of the determinants of a nation's ability to produce comm...
Contrary to an accepted wisdom, this paper shows that cross-country variations in the number of pate...
International comparisons of patent systems are essential to harmonization treaties and to analyze e...
International comparisons of patent systems are essential to harmonization treaties and to analyze e...
This paper examines the sources of Europe's lagging business R&D performance relative to the US, par...
Has the USA overtaken Europe as the powerhouse of new medicines? If so, is this attributable to a fl...
International patenting activity is a source of international technology diffusion.� However, techno...
Has the USA overtaken Europe as the powerhouse of new medicines? If so, is this attributable to a fl...
International audienceThis paper addresses the question of national differences as regard the number...
We investigate cross country differences in patent propensity in the European Union using the Europe...
In this article, we empirically investigate the effect of Research and Development (R&D) flows o...
This chapter uses patent applications as an innovation indicator and compares the trends and Structu...
This paper examines whether there are differences in private R&D investment performance between the ...
This paper examines whether there are differences in private R&D investment performance between the ...
This paper examines whether there are differences in private R&D investment performance between the ...
This paper offers an empirical examination of the determinants of a nation's ability to produce comm...
Contrary to an accepted wisdom, this paper shows that cross-country variations in the number of pate...
International comparisons of patent systems are essential to harmonization treaties and to analyze e...
International comparisons of patent systems are essential to harmonization treaties and to analyze e...
This paper examines the sources of Europe's lagging business R&D performance relative to the US, par...
Has the USA overtaken Europe as the powerhouse of new medicines? If so, is this attributable to a fl...
International patenting activity is a source of international technology diffusion.� However, techno...
Has the USA overtaken Europe as the powerhouse of new medicines? If so, is this attributable to a fl...